The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche’s Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Itamar Medical Q3 EPS $(0.28) Down From $(0.15) YoY, Sales $13.60M Up From $11.00M YoY
Itamar Medical (NASDAQ:ITMR) reported quarterly losses of $(0.28) per share. This is a 86.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $13.60 million in sales
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
SVB Leerink Downgrades Itamar Medical to Market Perform, Raises Price Target to $31
SVB Leerink analyst Richard Newitter downgrades Itamar Medical (NASDAQ:ITMR) from Outperform to Market Perform and raises the price target from $30 to $31.
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera’s COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 16)
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 14)
Ladenburg Thalmann Downgrades Itamar Medical to Neutral, Announces $33.85 Price Target
Ladenburg Thalmann analyst Jeffrey Cohen downgrades Itamar Medical (NASDAQ:ITMR) from Buy to Neutral and announces $33.85 price target.
